Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncology Nursing | 4 | 2021 | 16 | 1.860 |
Why?
|
| Neoplasms | 5 | 2020 | 1392 | 1.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 36 | 1.170 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 666 | 0.950 |
Why?
|
| Competency-Based Education | 1 | 2024 | 30 | 0.860 |
Why?
|
| Education, Nursing, Graduate | 1 | 2024 | 51 | 0.820 |
Why?
|
| Advance Care Planning | 1 | 2021 | 66 | 0.650 |
Why?
|
| Curriculum | 1 | 2024 | 606 | 0.650 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2019 | 8 | 0.620 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 25 | 0.610 |
Why?
|
| Lutetium | 1 | 2018 | 2 | 0.580 |
Why?
|
| Octreotide | 1 | 2018 | 4 | 0.580 |
Why?
|
| Somatostatin | 1 | 2018 | 21 | 0.580 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 14 | 0.580 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 210 | 0.580 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 23 | 0.570 |
Why?
|
| Chemoprevention | 1 | 2018 | 41 | 0.560 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 83 | 0.550 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 192 | 0.540 |
Why?
|
| Carcinogenesis | 1 | 2018 | 131 | 0.510 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 89 | 0.490 |
Why?
|
| DNA Damage | 1 | 2018 | 289 | 0.480 |
Why?
|
| Genetic Testing | 1 | 2017 | 140 | 0.480 |
Why?
|
| Sepsis | 1 | 2020 | 290 | 0.480 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2015 | 19 | 0.470 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 350 | 0.450 |
Why?
|
| Nurse's Role | 1 | 2015 | 120 | 0.430 |
Why?
|
| Medication Adherence | 1 | 2015 | 205 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 174 | 0.400 |
Why?
|
| Health Promotion | 1 | 2017 | 505 | 0.380 |
Why?
|
| Drug Eruptions | 1 | 2011 | 15 | 0.360 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 478 | 0.350 |
Why?
|
| Inflammation | 1 | 2018 | 1162 | 0.350 |
Why?
|
| Genomics | 1 | 2014 | 379 | 0.340 |
Why?
|
| ErbB Receptors | 1 | 2011 | 120 | 0.340 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 1211 | 0.330 |
Why?
|
| Signal Transduction | 2 | 2018 | 3070 | 0.320 |
Why?
|
| Humans | 12 | 2025 | 64251 | 0.230 |
Why?
|
| Transients and Migrants | 1 | 2025 | 26 | 0.220 |
Why?
|
| Education, Nursing, Baccalaureate | 1 | 2024 | 44 | 0.200 |
Why?
|
| Students, Nursing | 1 | 2024 | 89 | 0.190 |
Why?
|
| Goals | 1 | 2021 | 92 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2020 | 49 | 0.160 |
Why?
|
| Health Services for the Aged | 1 | 2020 | 49 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2024 | 728 | 0.150 |
Why?
|
| Nurse Practitioners | 1 | 2020 | 117 | 0.150 |
Why?
|
| Palliative Care | 1 | 2021 | 239 | 0.150 |
Why?
|
| Community Health Services | 1 | 2020 | 127 | 0.140 |
Why?
|
| Female | 6 | 2025 | 33360 | 0.140 |
Why?
|
| Aged | 4 | 2020 | 14657 | 0.140 |
Why?
|
| HIV Infections | 1 | 2025 | 976 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5527 | 0.140 |
Why?
|
| Adult | 4 | 2025 | 17121 | 0.130 |
Why?
|
| Middle Aged | 4 | 2025 | 17906 | 0.130 |
Why?
|
| Caregivers | 1 | 2020 | 283 | 0.120 |
Why?
|
| Communication | 1 | 2021 | 587 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 726 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 870 | 0.110 |
Why?
|
| Male | 5 | 2025 | 30305 | 0.110 |
Why?
|
| Nurse-Patient Relations | 1 | 2015 | 43 | 0.110 |
Why?
|
| Massachusetts | 2 | 2020 | 2094 | 0.110 |
Why?
|
| Boston | 1 | 2015 | 255 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2015 | 374 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 727 | 0.100 |
Why?
|
| Registries | 1 | 2017 | 885 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2015 | 575 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2047 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 374 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 26 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2015 | 1019 | 0.090 |
Why?
|
| Nursing Assessment | 1 | 2011 | 40 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2017 | 2019 | 0.090 |
Why?
|
| Nursing Methodology Research | 1 | 2011 | 53 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1272 | 0.090 |
Why?
|
| Mutation | 1 | 2017 | 2629 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2020 | 6732 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 788 | 0.070 |
Why?
|
| Child | 1 | 2017 | 4583 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2737 | 0.070 |
Why?
|
| Young Adult | 1 | 2017 | 4780 | 0.060 |
Why?
|
| Adolescent | 1 | 2017 | 6304 | 0.060 |
Why?
|
| Haiti | 1 | 2025 | 15 | 0.060 |
Why?
|
| Dominican Republic | 1 | 2025 | 25 | 0.060 |
Why?
|
| Social Stigma | 1 | 2025 | 74 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2025 | 539 | 0.050 |
Why?
|
| Health Behavior | 1 | 2025 | 474 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2025 | 728 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 771 | 0.040 |
Why?
|